Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for cardiometabolic diseases. The collaboration is valued up to $354m, but financial ...

MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs The collaboration provides external validation of MultiOmic Health’s AI-enabled precision ...

Cancer-killing T cells have been programmed to have two levels of specificity. First, the T cells have been equipped with a receptor sensitive to a protein that is found only in central nervous system ...

The development of gene editing tools, which enable the specific targeting and correction of mutations, hold the promise of allowing us to correct those mutations that cause genetic diseases. However, ...

Fig. 2 Examples of ionizable lipids, sterols, phospholipids, and PEG-lipids used in LNP formulations. Created with BioRender.com. Fig. 3 High-throughput screening of the 3-component ionizable ...

Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.

Scientists have engineered dual-membrane nanoparticles that home in on heart tissue after a heart attack, delivering regenerative molecules while evading the body’s immune defences. Image Credit: tong ...

Multiomic Health Ltd. and Alloy Therapeutics Inc. have signed a memorandum of understanding to jointly discover and develop first-in-class renal tissue-targeting drugs. Precision medicines for chronic ...